Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03344627
Other study ID # ID07-60-19
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 27, 2017
Est. completion date December 31, 2018

Study information

Verified date March 2019
Source Mahidol University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Sepsis and septic shock patients are considered to have a high risk of complications and death. Appropriate antimicrobial therapy plays an important role in determining outcomes in septic patients. However, pathophysiologic changes associated with critical illness have an impact on pharmacokinetics of antimicrobials. In addition, increasing bacterial resistance is also a growing concern, especially in intensive care units., Consequently, standard antimicrobial dose may not be sufficient to achieve pharmacokinetic/pharmacodynamic target in sepsis and septic shock patients. The purpose of this study is to compare a therapy between meropenem standard dose and meropenem high dose in the treatment of sepsis and septic shock


Recruitment information / eligibility

Status Completed
Enrollment 76
Est. completion date December 31, 2018
Est. primary completion date November 30, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adults (18 years and older) with sepsis and/or septic shock according to SEPSIS-3 criteria and receive meropenem within 1 hour after diagnosis

- Informed consent signed by patient or their legally authorized representative

Exclusion Criteria:

- Subjects with infective endocarditis

- Subjects with central nervous system infection

- Subjects who requires surgical condition within 72 hours after randomization

- Subjects on extracorporeal membrane oxygenation (ECMO) within 3 days after randomization

- Subjects with active seizure

- History of receiving meropenem within 1 week prior to randomization

- Pregnancy women and lactation

- Known allergy to meropenem

- Not complete a 72-hour course of empirical meropenem treatment

Study Design


Intervention

Drug:
Meropenem standard dose
Empirical with 1 g meropenem intravenous infusion in 30 minutes then 1 g intravenous infusion in 3 hours every 8 hours. Dosage is adjusted in case of renal dysfunction. Duration of therapy is varied regarding source(s) of infection.
Meropenem high dose
Empirical with 2 g meropenem intravenous infusion in 30 minutes then 2 g intravenous infusion in 3 hours every 8 hours. Dosage is adjusted in case of renal dysfunction. Duration of therapy is varied regarding source(s) of infection

Locations

Country Name City State
Thailand Faculty of Medicine Ramathibodi Hospital Ratchathewi Bangkok

Sponsors (1)

Lead Sponsor Collaborator
Mahidol University

Country where clinical trial is conducted

Thailand, 

References & Publications (7)

Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev. 2014 Nov 20;77:3-11. doi: 10.1016/j.addr.2014.07.006. Epub 2014 Jul 15. Review. — View Citation

de Grooth HJ, Geenen IL, Girbes AR, Vincent JL, Parienti JJ, Oudemans-van Straaten HM. SOFA and mortality endpoints in randomized controlled trials: a systematic review and meta-regression analysis. Crit Care. 2017 Feb 24;21(1):38. doi: 10.1186/s13054-017-1609-1. Review. — View Citation

Jaruratanasirikul S, Thengyai S, Wongpoowarak W, Wattanavijitkul T, Tangkitwanitjaroen K, Sukarnjanaset W, Jullangkoon M, Samaeng M. Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units. Antimicrob Agents Chemother. 2015;59(6):2995-3001. doi: 10.1128/AAC.04166-14. Epub 2015 Mar 9. — View Citation

Marquet K, Liesenborgs A, Bergs J, Vleugels A, Claes N. Incidence and outcome of inappropriate in-hospital empiric antibiotics for severe infection: a systematic review and meta-analysis. Crit Care. 2015 Feb 16;19:63. doi: 10.1186/s13054-015-0795-y. Review. — View Citation

Mouton JW, van den Anker JN. Meropenem clinical pharmacokinetics. Clin Pharmacokinet. 1995 Apr;28(4):275-86. Review. — View Citation

Roberts JA, Kumar A, Lipman J. Right Dose, Right Now: Customized Drug Dosing in the Critically Ill. Crit Care Med. 2017 Feb;45(2):331-336. doi: 10.1097/CCM.0000000000002210. — View Citation

Suwantarat N, Carroll KC. Epidemiology and molecular characterization of multidrug-resistant Gram-negative bacteria in Southeast Asia. Antimicrob Resist Infect Control. 2016 May 4;5:15. doi: 10.1186/s13756-016-0115-6. eCollection 2016. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary SOFA score change The Sequential organ failure assessment (SOFA) score describe the time course of multiple organ dysfunction.
The SOFA score is composed of scores for six organ systems (respiratory, cardiovascular, neurological, hepatic, renal and coagulation).
The function of six organ systems is scored from 0 (no organ dysfunction) to 4 (severe organ dysfunction), and the individual organ scores are then summed to a total score between 0 and 24.
Primary outcome is assessing change between SOFA score at baseline and SOFA score at day 4 after treatment by meropenem
Change from Baseline SOFA score at day 4
Secondary Mortality In hospital mortality 14 and 28 days
Secondary Clinical cure Composite of:
Persistent fever and/or
Stable or increased white blood cell count
Day 3, 5, 7, 10 and 14
Secondary Microbiological cure Elimination of the study entry pathogen within 14 days after received meropenem
Bacteremia: no growth in blood cultures
Intra-abdominal infection: no growth in blood cultures
UTI: uropathogen growth of less than 10^4 CFU/mL in women or less than 10^3 CFU/mL in men
HAP/VAP: pathogen in sputum culture growth of less than 10^3 CFU/mL
SSTI: no growth in blood cultures
Day 3, 5, 7, 10 and 14
Secondary Duration of vasopressor agents Time interval (day) from time of vasopressor agents initiation to time to vasopressor agents discontinuation 14 and 28 days
Secondary Duration of mechanical ventilator Time interval (day) of mechanical ventilator 14 and 28 days
Secondary Length of ICU stay Time interval (day) from ICU admission (after randomization) to ICU discharge 14 and 28 days
Secondary Length of hospital stay Time interval (day) from hospital admission (after randomization) to hospital discharge 14 and 28 days
Secondary %T > MIC % time of meropenem concentration above MIC Day 1
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3